Aberdeen Group plc Has $414.20 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Aberdeen Group plc raised its stake in Johnson & Johnson to approximately $414.2 million, making it the company's 18th largest position in its investment portfolio.
• Executive Vice President Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson for over $10 million, decreasing her ownership by 24.08%.
• Johnson & Johnson announced a quarterly dividend of $1.30, resulting in a 2.7% yield, with a current dividend payout ratio of 55.61%.

Aberdeen Group plc raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,729,049 shares of the company's stock after buying an additional 20,450 shares during the period. Johnson & Johnson accounts for about 0.7% of Aberdeen Group plc's investment portfolio, making the stock its 18th biggest position. Aberdeen Group plc owned 0.11% of Johnson & Johnson worth $414,201,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $35,000. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $48,000. Finally, von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $49,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Down 0.2%

Shares of NYSE JNJ opened at $190.66 on Monday. The company's 50 day simple moving average is $178.48 and its 200 day simple moving average is $163.78. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The firm has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion for the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Royal Bank Of Canada reiterated an "outperform" rating and set a $209.00 target price on shares of Johnson & Johnson in a research report on Friday. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Citigroup upped their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a "buy" rating in a research report on Tuesday, October 7th. Finally, The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a "buy" rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.